Italia markets close in 4 hours 47 minutes

XOMA Corporation (0M26.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
24,50+6,26 (+34,32%)
Al 07:00PM GMT. Mercato aperto.
Schermo intero
Chiusura precedente18,24
Aperto0,00
Denaro0,00 x N/D
Lettera0,00 x N/D
Min-Max giorno0,00 - 0,00
Intervallo di 52 settimane
Volume1.260
Media VolumeN/D
CapitalizzazioneN/D
Beta (5 anni mensile)0,82
Rapporto PE (ttm)0,24
EPS (ttm)1,00
Prossima data utili03 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon

    XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay Potential to earn $475 million in development, regulatory, and sales milestones Low- to mid- teens royalties upon commercialization Expands XOMA’s portfolio into new therapeutic segment – women’s health EMERYVILLE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), a biotech royalty aggregator playing a dist

  • GlobeNewswire

    XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events

    Received first recurring royalty-style payment from Roche related to faricimab, its newly launched therapy for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). First five months of sales in the U.S. and initial sales in Japan resulted in a $0.5 million cash payment to XOMA. Paid $3.0 million milestone to Affitech S.A. triggered by the European Commission’s approval of Roche’s VABYSMO® (faricimab-svoa) for the treatment of wAMD and DME. Received $2.5 million milestone

  • GlobeNewswire

    XOMA Declares Quarterly Preferred Stock Dividends

    EMERYVILLE, Calif., Sept. 21, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series